Primmune Therapeutics
Biotechnology ResearchCalifornia, United States2-10 Employees
Primmune Therapeutics is developing an orally administered TLR7 agonist to stimulate innate immunity in cancer immunotherapy. Our goal is to improve the response rate of patients to current and future immunotherapy medicines.